Please ensure Javascript is enabled for purposes of website accessibility

Should You Buy Smith & Nephew Today?

By Royston Wild - Apr 11, 2013 at 5:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

How attractive are the shares of Smith & Nephew (LON: SN)?

LONDON -- Shares in Smith & Nephew (SN 1.41%) (SNN 1.37%) have risen steadily in recent months, and were recently up 11% in the year to date.

And I believe that the company's concerted drive toward higher-growth areas and regions should drive the stock higher as earnings and dividends head northwards. Citi have plonked a 797 pence price target on the company's stock, providing chunky upside from current levels.

Transformation plan to deliver excellent rewards
Smith & Nephew is changing its product mix to focus on more lucrative markets, and late last year purchased Healthpoint Biotherapeutics -- a leader in the area of wound management -- as it seeks to address sales difficulties in other areas of the group

The health care giant is also looking to significantly boost its operations in lucrative developing markets to offset weakness in its traditional geographies. The company saw growth of just 1% in the US in quarter four, it announced in February, 2% in its Other Established Markets, and 14% in its Emerging and International Markets division.

The firm announced the acquisition of Brazilian sports medicine, trauma product and orthopaedic reconstruction distributor Pro Cirugia Especializada earlier this month. And the company's healthy balance sheet should support further M&A activity moving forward.

Earnings growth expected to accelerate
Earnings per share are set to rise 3% in 2013 to 51 pence, according to City forecasters, before picking up speed next year to rise 9% to 55 pence.

The company has registered solid annual earnings growth dating back a number of years, and this has helped it to develop a progressive dividend policy -- indeed, the company hiked its final dividend 50% to 16.2 cents (10.5 pence) per share last year, providing a total dividend of 26.1 cents.

And analysts expect this to keep heading higher, with total payouts of 17.6 pence and 19.3 pence predicted for this year and next, respectively. Dividend yields for these years are expected to come in below the current 3.3% FTSE 100 average, at 2.3% and 2.6%, respectively, although rapid growth could see it shoot above the average in coming years. And these payouts are extremely well protected, with coverage of 2.9 times for the next two years well above the widely regarded benchmark of 2 times.

Smith and Nephew currently changes hands on a P/E rating of 14.9 and 13.7 for 2013 and 2014, respectively, providing a discount to a forward earnings multiple of 15 for the entire health care equipment and services sector. In my opinion the likelihood of solid earnings growth and robust dividend increases make the company an excellent pick for investors.

The canny guide for clever investors
If you already hold shares in Smith and Nephew, check out this newly updated special report that highlights a host of other FTSE winners identified by ace fund manager Neil Woodford.

Woodford -- head of UK Equities at Invesco Perpetual -- has more than 30 years' experience in the industry, and has identified two other fantastic health care plays in the report set to deliver spectacular investor returns.

The report, compiled by The Motley Fool's crack team of analysts, is totally free and comes with no further obligation. Click here now to download your copy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Smith & Nephew plc Stock Quote
Smith & Nephew plc
SNN
$31.80 (1.37%) $0.43
Smith & Nephew plc Stock Quote
Smith & Nephew plc
SN
$1,294.00 (1.41%) $18.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.